logo
Products
Services
Resources
Selection Guides
About
iFluor® 750 Anti-human CD38 Antibody
HB7
HB7 is an anti-human monoclonal antibody that recognizes the CD38 antigen. CD38 (alternatively called ADP-ribosyl cyclase or T10) is a 45 kD transmembrane glycoprotein that is expressed on the surface of cells such as B cells, dendritic cells and macrophages. CD38 is a component of critical cellular pathways, for instance, the apoptotic signaling pathway and B cell receptor signaling pathway. In addition, in many organisms, it is a repressor of bone resorption, is involved in the positive regulation of cell growth and is involved in the positive regulation of vasoconstriction. From a research standpoint, it is of biological interest due to its association with essential macromolecules/ligands such as hyaluronic acid and CD16. CD38 is a moderately popular antibody target, with over 15000 publications in the last decade. CD38 is typically used in flow cytometry applications as a phenotypic marker for differentiation of cell types, specifically in the study of immunology. This antibody was purified through affinity chromatography and conjugated to iFluor® 750 (ex/em = 757/779 nm).
product image
CatalogSize
Price
Quantity
103820L0100 tests
Price
103820L1500 tests
Price
 
Antibody properties

Other namesADP-ribosyl cyclase, T10
CloneHB7
HostMouse
IsotypeIgG1, kappa
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Correction factor (260 nm)0.044
Correction factor (280 nm)0.039
Correction factor (565 nm)0.0250
Correction factor (650 nm)0.1413
Extinction coefficient (cm -1 M -1)
275000
1
Excitation (nm)757
Emission (nm)779
Quantum yield
0.12
1
Usage and storage

Intended useResearch Use Only (RUO)
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on August 19, 2026